Clinical Trials on Refractory Multiple Myeloma

Total 14094 results

National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Cristiana Costa Chase, DO

Not yet recruiting

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (COSTA)

Relapsed/Refractory Multiple Myeloma

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
University of Leeds

Completed

Selinexor, Cyclophosphamide and Prednisone in Myeloma (MUKtwelve)

Relapsed or Refractory Multiple Myeloma

United Kingdom
Memorial Sloan Kettering Cancer Center
Exelixis

Completed

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Sun Yat-sen University
China Food and Drug Administration

Withdrawn

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Relapse/Refractory Multiple Myeloma

China
University of Illinois at Chicago

Completed

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03) (BMT-03)

Multiple Myeloma, Relapsed | Multiple Myeloma, Refractory to Standard Treatment

United States
Shanghai Theorion Pharmaceutical Co Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Unknown

Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

China
Oncotherapeutics

Withdrawn

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Plasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Epizyme, Inc.

Recruiting

A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Diffuse Large B Cell Lymphoma Refractory | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Sweden, Belgium, Australia, Netherlands, Canada, Poland
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
Medical College of Wisconsin

Withdrawn

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma
National Cancer Institute (NCI)

Completed

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Stage III Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific | Refractory Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain Only

United States
Oncotherapeutics

Not yet recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Marcela V. Maus, M.D.,Ph.D.

Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
University of Washington

Recruiting

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Multiple Myeloma | Plasma Cell Leukemia | Recurrent Multiple Myeloma

United States
Indapta Therapeutics, INC.

Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple Myeloma | Refractory Multiple Myeloma | Refractory Non-Hodgkin Lymphoma | NHL | Blood Cancer | Relapsed Multiple Myeloma | Relapsed Non-Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Not yet recruiting

Marizomib Central Nervous System (CNS)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Andrew Yee, MD
Janssen Research & Development, LLC; Amgen

Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Multiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in Relapse

United States
National Cancer Institute (NCI)

Completed

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Stage III Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific | Refractory Multiple Myeloma | Refractory Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Malignant Neoplasm | Myeloproliferative Neoplasm | Indolent Non-Hodgkin Lymphoma | Acute Myeloid Leukemia in Remission | Refractory Anemia | Refractory Anemia With... and other conditions

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Hellenic Society of Hematology
Janssen Pharmaceuticals

Completed

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment (DARE)

Relapsed/Refractory Multiple Myeloma

Greece
University Hospital, Montpellier
Poitiers University Hospital

Unknown

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Patients With Recurrent or Refractory Multiple Myeloma

France
University of Pennsylvania

Recruiting

CART-38 in Adult AML and MM Patients

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM)

United States
Shahid Beheshti University of Medical Sciences

Not yet recruiting

Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

Iran, Islamic Republic of
University of Pennsylvania
Genentech, Inc.

Recruiting

Cevostamab Following CAR T Cell Therapy for RRMM

Relapsed/Refractory Multiple Myeloma

United States
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Refractory

China
Oncotherapeutics
Karyopharm Therapeutics Inc

Recruiting

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Refractory Multiple Myeloma

United States
Karyopharm Therapeutics Inc

Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Multiple Myeloma, Refractory

Israel, Greece
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Recruiting

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, France
University of Maryland, Baltimore

Active, not recruiting

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
NexImmune Inc.

Suspended

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma

United States

Clinical Trials on Refractory Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations